文献速递类风湿关节炎其他结缔组织病

持续使用JAK抑制剂对免疫介导炎症性疾病患者带状疱疹再激活风险的影响:韩国全国性人群研究

Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea.
PubMed 文献 · Semin Arthritis Rheum · 2024-01-12

该韩国全国性人群研究分析2007至2021年类风湿关节炎或溃疡性结肠炎患者数据,纳入3947例接受JAK抑制剂治疗者,其中611例(15.5%)发生带状疱疹再激活。对460例带状疱疹后再激活风险分析显示,继续用药组与停药组后续再激活发生率无显著差异(5.3/100人年 vs 5.9/100人年,P=0.52),校正后持续用药并非显著危险因素(校正HR 0.71,95%CI 0.29-1.72,P=0.45)。作者认为免疫介导炎症性疾病患者即使发生带状疱疹再激活后仍可维持JAK抑制剂治疗。

要点

  • 3947例接受JAK抑制剂治疗者中611例(15.5%)发生带状疱疹再激活,发生率8.38/100人年。
  • 带状疱疹再激活后继续JAK抑制剂组与停药组后续再激活率无显著差异(5.3/100 vs 5.9/100人年,P=0.52)。
  • 校正年龄、性别、糖皮质激素及抗病毒药使用后,持续JAK抑制剂非后续再激活显著危险因素(校正HR 0.71,95%CI 0.29-1.72,P=0.45)。

核心结论

  • 在类风湿关节炎或溃疡性结肠炎患者中,持续使用JAK抑制剂与后续带状疱疹再激活的显著风险无关。
  • 作者认为免疫介导炎症性疾病患者即使发生带状疱疹再激活后仍可维持JAK抑制剂治疗。

研究设计与样本

  • 韩国全国性人群研究,基于韩国健康保险审查评价院(HIRA)2007至2021年类风湿关节炎或溃疡性结肠炎患者数据。
  • 共3947例接受JAK抑制剂治疗者纳入分析(类风湿关节炎3540例,溃疡性结肠炎407例)。
  • 发生带状疱疹再激活后排除151例缺乏后续数据者,对460例进行后续再激活风险分析(继续JAK抑制剂组386例[83.9%],停药组74例[16.1%])。

主要发现

  • 中位治疗0.95年(IQR 0.93-2.58)后,611例(15.5%)发生带状疱疹再激活,发生率8.38/100人年。
  • 后续中位随访1.11年(IQR 0.53-1.91)期间,继续JAK抑制剂组36例(9.3%)和停药组6例(8.1%)发生带状疱疹再激活。
  • 后续再激活发生率两组无显著差异(5.3/100人年 vs 5.9/100人年,P=0.52)。
  • 校正年龄、性别、糖皮质激素使用及抗病毒药物使用后,持续使用JAK抑制剂非后续带状疱疹再激活的显著危险因素(校正HR 0.71,95%CI 0.29-1.72,P=0.45)。

临床怎么用

  • 作者认为免疫介导炎症性疾病患者即使发生带状疱疹再激活后仍可维持JAK抑制剂治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the risk of recurrent herpes zoster (HZ) reactivation under continued Janus kinase inhibitor (JAKi) therapy in patients with immune-mediated inflammatory diseases (IMID) who developed HZ reactivation. METHODS: Data from the Korean Health Insurance Review and Assessment Service (HIRA) of patients with rheumatoid arthritis (RA) or ulcerative colitis (UC) gathered from 2007 to 2021 were analyzed. RESULTS: A total of 3947 (RA 3540, UC 407) receiving JAKi were included. After median 0.95 years (IQR, 0.93-2.58) of therapy, 611 (15.5%) patients developed HZ reactivation (incidence rate: 8.38/100 person-years [PY]). After excluding 151 patients with lack of data after HZ reactivation, 460 patients (JAKi continuation group, n = 386 [83.9%]; JAKi discontinuation group, n = 74 [16.1%]) were analyzed for the risk of subsequent recurrent HZ reactivation. During further follow-up of median 1.11 years (IQR, 0.53-1.91), 36 (9.3%) and 6 (8.1%) patients in the JAKi continuation group and JAKi discontinuation group experienced a recurrence of HZ, respectively. The incidence rate of subsequent recurrent HZ reactivation was not significantly different between the two groups (5.3/100 vs. 5.9/100 PY; P = 0.52). After adjusting for age, sex, usage of corticosteroids, and antiviral agents, continued use of JAKi was not a significant risk factor for subsequent HZ reactivation (adjusted hazard ratio, 0.71 [CI, 0.29-1.72], P = 0.45). CONCLUSION: In this nationwide population-based study on patients with RA or UC, continued use of JAKi was not associated with a significant risk of subsequent recurrent HZ reactivation. JAKi therapy may be maintained in patients with IMID even after HZ reactivation.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kim YE, Kim YJ, Jeong DH, et al. Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea. Semin Arthritis Rheum. 2024. PMID: 38281468. doi:10.1016/j.semarthrit.2024.152362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。